Associate Professor, Medicine - Hematology, Stanford University Medical Center
Hematology
Dr. Steven E. Coutre, MD
|
|
Give Review
Steven Coutre is an expert in the field of Hematology. He researched medicine at Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine is ranked 2/25 in Research/PrimaryCare. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "America's Top Doctors for Cancer". Steven Coutre is also published. He has 55 publications published. The lastest publication: "Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Tamibarotene in patients with Acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- A pediatric case of T-cell prolymphocytic Leukemia.
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia.
- Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell Lymphoma (MCL).
- Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic Leukemia.
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin Lymphoma.
- SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory Acute lymphocytic leukaemia.
- Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk Acute promyelocytic leukaemia may eliminate the need for maintenance...
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- Ibrutinib as initial therapy for elderly patients with Chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
- A phase II trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with Acute myeloid leukemia.
- Acute Myeloid Leukemia, Version 2.2013.
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory Myeloma.
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic Leukemia.
- Treatment of adults with Acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial.
- High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
- Oral sapacitabine for the treatment of Acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
- Tailored temozolomide therapy according to MGMT methylation status for elderly patients with Acute myeloid leukemia.
- Acute myeloid leukemia.
- Optimizing therapy for Acute myeloid leukemia.
- Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer.
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage Acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Grou...
- Von Willebrand Disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval.
- Refractory hematuria from amyloidosis successfully treated by splenectomy.
- Acute myeloid leukemia clinical practice guidelines in oncology.
- The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic Leukemia: implications for diagnosis, classification, and management.
- PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced Myeloproliferative disease.
- A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic Syndrome.
- Management of advanced chronic lymphocytic Leukemia.
- Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic Leukemia and prolymphocytic Leukemia.
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous Leukemia in myeloid blast crisis: results of a phase II study.
- Treatment advances have not improved the early death rate in Acute promyelocytic leukemia.
- Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic Leukemia and multiple myeloma.
- Arsenic trioxide improves event-free and overall survival for adults with Acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
- Second-line mitoxantrone, etoposide, and cytarabine for Acute myeloid leukemia: a single-center experience.
- Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory Acute lymphocytic leukaemia.
- Classification and risk stratification for Acute promyelocytic leukemia.
- CD137 stimulation enhances the antiLymphoma activity of anti-CD20 antibodies.
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
- Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive Acute lymphoblastic leukemia with resistance or i...
- International standardized approach for flow cytometric residual disease monitoring in Chronic lymphocytic leukaemia.
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid Leukemia in blast crisis.
- Therapeutic efficacy and safety of Platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
- Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass.
- NCCN Practice Guidelines for Acute Myelogenous Leukemia.
- Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
- T-cell prolymphocytic Leukemia: update and focus on alemtuzumab (Campath-1H).
- Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro.
- A subset of human rosetted lymphocytes contains previously unidentified histamine.
- Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid Leukemia in blast phase.
- Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple Myeloma.
- Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities.
- Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell Acute lymphoblastic leukemia.
Schools
Stanford University School Of Medicine
Yale New Haven Hospital
Stanford University School Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- America's Top Doctors for Cancer
Education
-
Yale-New Haven Hospital -
Stanford University School of Medicine
Hospital
-
Stanford Health Care
Drug Facts
| NPI NUMBER | 1073600441 | |
| NPPES Provider LastName | COUTRE | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 943042205 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology | |
| Total Claim Count | 527.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073600441 |
| Last Name Of The Provider | COUTRE |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
|
Dr. Branimir I. Sikic, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rondeep S. Brar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory Heestand, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dita A. Gratzinger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravindra Majeti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Miller, MD |
|
|
Dr. Saul A. Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley L. Schrier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander J. Ungewickell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert D. Stebbins, MD |
|
|
Dr. Steven K. Foung, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beverly S. Mitchell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tanaya Shree, MD |
|
|
Dr. Beth A. Martin-Kool, MD
This Doctor is OpenDoctor Recommended.
|